Developing scientific confidence in HTS-derived prediction models: Lessons learned from an endocrine case study  by Cox, Louis Anthony (Tony) et al.
Regulatory Toxicology and Pharmacology 69 (2014) 443–450Contents lists available at ScienceDirect
Regulatory Toxicology and Pharmacology
journal homepage: www.elsevier .com/locate /yr tphDeveloping scientiﬁc conﬁdence in HTS-derived prediction models:
Lessons learned from an endocrine case studyhttp://dx.doi.org/10.1016/j.yrtph.2014.05.010
0273-2300/ 2014 The Authors. Published by Elsevier Inc.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
⇑ Corresponding author. Fax: +1 202 488 2503.
E-mail addresses: tcoxdenver@aol.com (L.A. (T.) Cox), doug@cox-associates.com
(D. Popken), MSMarty@dow.com (M.S. Marty), JCRowlands@dow.com
(J.C. Rowlands), patlewig@hotmail.com (G. Patlewicz), katy.o.goyak@exxonmobil.
com (K.O. Goyak), Rick_Becker@americanchemistry.com (R.A. Becker).Louis Anthony (Tony) Cox a, Douglas Popken a, M. Sue Marty b, J. Craig Rowlands b, Grace Patlewicz c,
Katy O. Goyak d, Richard A. Becker e,⇑
aCox Associates, 503 Franklin St, Denver, CO 80218, USA
b The Dow Chemical Company, Toxicology & Environmental Research & Consulting, 1803 Building Washington Street, Midland, MI 48674, USA
cDuPont Haskell Global Centers for Health and Environmental Sciences, Stine 320/212, 1090 Elkton Road, Newark, DE 19711, USA
d ExxonMobil Biomedical Sciences Inc., 1545 Route 22, East Annandale, NJ 08801, USA
eRegulatory and Technical Affairs Department, American Chemistry Council (ACC), 700, 2nd Street NE, Washington, DC 20002, USA
a r t i c l e i n f oArticle history:
Received 2 February 2014
Available online 17 May 2014
Keywords:
Validation framework
High throughput/high content assays
Prediction models
Adverse outcome pathways
Endocrinea b s t r a c t
High throughput (HTS) and high content (HCS) screening methods show great promise in changing how
hazard and risk assessments are undertaken, but scientiﬁc conﬁdence in such methods and associated
prediction models needs to be established prior to regulatory use. Using a case study of HTS-derived
models for predicting in vivo androgen (A), estrogen (E), thyroid (T) and steroidogenesis (S) endpoints
in endocrine screening assays, we compare classiﬁcation (ﬁtting) models to cross validation (prediction)
models. The more robust cross validation models (based on a set of endocrine ToxCast™ assays and
guideline in vivo endocrine screening studies) have balanced accuracies from 79% to 85% for A and E,
but only 23% to 50% for T and S. Thus, for E and A, HTS results appear promising for initial use in setting
priorities for endocrine screening. However, continued research is needed to expand the domain of
applicability and to develop more robust HTS/HCS-based prediction models prior to their use in other
regulatory applications. Based on the lessons learned, we propose a framework for documenting scientiﬁc
conﬁdence in HTS assays and the prediction models derived therefrom. The documentation, transparency
and the scientiﬁc rigor involved in addressing the elements in the proposed Scientiﬁc Conﬁdence Frame-
work could aid in discussions and decisions about the prediction accuracy needed for different
applications.
 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Advances in high throughput (HT) and high content (HC)
screening methods for quantifying and characterizing molecular
and cellular responses to chemicals are creating a new frontier in
toxicity testing and subsequent hazard and risk assessments
(Wetmore et al., 2012; Thomas et al., 2013). The National Academy
report ‘‘Toxicity Testing in the 21st Century: A Vision and a Plan’’
(NRC, 2007) has been embraced by the U.S. Environmental
Protection Agency (EPA) through its own computational toxicology
research program. Over the last 6 years, the EPA has actively pur-
sued its ToxCast™ program (http://www.epa.gov/ncct/toxcast/)
and was instrumental in establishing the Tox21 collaboration ofEPA, FDA, NIEHS/NTP and NIH (http://www.epa.gov/ncct/Tox21/),
launched in 2008, ‘‘to develop ways to predict potential toxicity
of chemicals and to develop a cost-effective approach for prioritiz-
ing the thousands of chemicals that need toxicity testing’’ (http://
www.epa.gov/ncct/Tox21/).
Actualizing the Tox21 vision entails two main components: (1)
HT/HC screening methods to construct quantitative biological
proﬁles of chemical substances, and (2) prediction models to inter-
pret these proﬁles in the appropriate context of hazard and risk
assessment. Such prediction models are typically derived in one
of three different approaches. One approach is to use HT/HC
screening methods as inputs to predict in vivo animal toxicity
study outcomes. A number of statistical ToxCast™ models have
been developed to predict adverse outcomes in animal toxicity
studies, including hepatocarcinogens (Shah et al., 2011), cancer
(Kleinstreuer et al., 2012), reproductive toxicity (Martin et al.,
2011) and prenatal developmental toxicity (Sipes et al., 2011).
For the most part, these models have been based on correlating
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(http://www.epa.gov/ncct/toxrefdb/). Similarly, Fielden et al., 2011
developed an approach for using genomic signatures to predict
nongenotoxic hepatocarcinogens in the rat.
A second alternative approach is to predict activity in speciﬁc
biological pathways. The ToxCast™ program has published a num-
ber of models for endocrine disruption pathways (Reif et al., 2010),
differentiation (Chandler et al., 2011) and angiogenesis
(Kleinstreuer et al., 2013), and Andersen and colleagues have
focused on pathways such as DNA damage and repair and PPARa
(Bhattacharya et al., 2011; McMullen et al., 2014). A third approach
could be termed a quantitative HT/HC screening-level chemical
safety assessment. In this third approach, rather than predicting
any speciﬁc hazard or pathway effect, HT/HC screening tools are
coupled with exposure information/data to derive putative safe
margins of exposure. This last approach appears to follow the
vision articulated in the NAS 2007 publication most closely.
Thomas et al. (2013) have used ToxCast™ assays and transcripto-
mics from short-term in vivo studies used to set benchmark doses
without constraining the speciﬁc gene responses to those necessar-
ily linked to known adverse outcomes. These benchmark doses are
then compared to estimates of human exposures to derive margin
of exposure metrics for determining safety.
Thus, understanding and evaluating the predictivity of HTS/HCS
models is an important aspect of regulatory acceptance and use of
Tox21 approaches. This can be both challenging and controversial.
Evaluation of model performance can be characterized, in part, by
evaluating sensitivity (positive predictivity) and speciﬁcity (nega-
tive predictivity). Balanced accuracy (BA) is the arithmetic mean
of sensitivity and speciﬁcity; the closer a value is to unity, the
greater the accuracy. Thomas et al. (2012) analyzed the suite of
endpoints in ToxRefDB, and reported (1) most in vivo endpoints
could not be predicted any better using the HT/HC ToxCast™ assay
data compared with chemical descriptor information (e.g., typical
inputs used in the development of QSAR models); (2) the ability
of ToxCast™ assays to predict most endpoints resulted in balanced
accuracies of less than 0.55; (3) past estimates of predictive perfor-
mance of models developed from ToxCast™ assays were likely
impacted by ‘‘preﬁltering the in vitro assay data outside the
cross-validation loop,’’ in other words, manually selecting a subset
of chemicals which were expected to be relatively predictable as
the basis for assessing predictive power. Dix and colleagues
responded that failing to incorporate knowledge of biological or
adverse outcome pathways needlessly limits the purely statistical
approach to classiﬁcation, making its predictive power less than
it would and should be if relevant biological, chemical, and toxico-
logical knowledge were used to select relevant predictors (Dix
et al., 2012). Clearly, greater attention needs to be drawn to how
HTS/HCS derived prediction models are constructed and evaluated.2. Case study: evaluation of estrogen, androgen and thyroid
prediction models of Rotroff et al. (2013)
To better understand the impact of classiﬁcation versus model-
ing using cross validation, we used the endocrine screening predic-
tion models published by Rotroff et al. (2013) as a case study. This
example was of particular interest given the EPA’s plan to enhance
the efﬁciency of its Endocrine Disruption Screening Program
(EDSP) with HTS assays from the ToxCast program to achieve the
vision described as EDSP21(EPA, 2011). EPA’s current EDSP
(http://www.epa.gov/endo/) is a two tiered screening and testing
program. EDSP Tier I (EDSP T1S) consists of a battery of in vitro
and in vivo screening assays designed to evaluate the potential of
chemicals to interact with the Estrogen, Androgen or Thyroid
(EAT) hormone systems. EDSP Tier II is comprised of in vivo testswhich are intended to be used for Tier 1 positive substances to
evaluate adverse effects, NOAELs and dose response for use in risk
assessment (EPA, 2009). Under EDSP21, EPA plans to use HTS
assays and prediction models ﬁrst for priority setting, then to
replace certain EDSP T1S assays and ﬁnally, if scientiﬁcally sup-
portable, to fully replace EDSP T1S altogether (EPA, 2011).
To select a set of substances with robust data, Rotroff et al.
(2013) used the data from two sources: (1) guideline study data
generated during the validation of several EDSP in vivo endocrine
screening assays (e.g., uterotrophic, Hershberger assay, intact male,
ﬁsh short-term reproduction, and the male and female pubertal
assays, etc.) and (2) non-guideline endocrine-related studies from
the open literature. For the same substances, relevant in vitro Tox-
Cast™ endocrine screening assay results were used as the basis for
construction of a set of models to predict results for in vivo estro-
gen receptor-, and androgen receptor-mediated responses in the
EDSP T1S in vivo assays (e.g., E responses in the uterotrophic, ﬁsh
short-term reproduction and pubertal female assays and A
responses in the Hershberger, ﬁsh short-term reproduction and
pubertal male assays). Rotroff et al. (2013) reported that ‘‘Tox-
Cast™ estrogen receptor and androgen receptor assays predicted
the results of relevant EDSP T1S assays with balanced accuracies
of 0.91 (p < 0.001) and 0.92 (p < 0.001), respectively,’’ concluding
that ‘‘[O]verall, results suggest that current ToxCast™ assays can
accurately identify chemicals with potential to interact with the
estrogenic and androgenic pathways, and could help prioritize
chemicals for EDSP T1S assays.’’
This case study aimed to (1) replicate the prediction models
derived by Rotroff et al. (2013) (referred to below as the ‘‘EPA
2013 HTS-derived EDSP T1S endocrine prediction models’’); (2)
evaluate the differences between model development using ﬁtting
and model development using cross validation; and (3) explore the
feasibility of deriving prediction models for EDSP outcomes either
using the full range of ToxCast™ assays or chemical speciﬁc infor-
mation (e.g., classical QSAR). Based upon the knowledge gained, we
describe a framework that may be useful to explicitly document
scientiﬁc conﬁdence in HTS/HCS assays and prediction models
derived therefrom, and discuss the case study in terms of the ele-
ments of this framework.
2.1. Data and methods
In vitro assay data and in vivo outcome data were obtained from
the Supplemental Data ﬁles provided in the online version of
Rotroff et al. (2013): Supplemental File 1 contained the data from
the ToxCast™ assays, while Supplemental File 3 contained the data
from the EDSP assays. Although there were over 500 individual
ToxCast™ assays in the EPA database, only 18 ToxCast™ assays
of three distinct types (i.e., competitive binding, enzyme inhibition,
and reporter gene assays) were included in Supplemental File 1,
with speciﬁc subsets of these applied to each of the four EDSP
assay classes: estrogen-, androgen-, steroidogenesis-, or thyroid-
related MOAs (guideline-E, guideline-A, guideline-S, guideline-T,
respectively). Although Rotroff et al. (2013) also compared the lim-
ited set of ToxCast™ thyroid-related results and the one ToxCast™
steroidogenesis assay with guideline and non-guideline studies,
the underlying datasets were so sparse that constructing and eval-
uating prediction models had limited utility. Rotroff et al. (2013)
thus concluded there is a ‘‘clear need to develop HTS assays
capable of detecting steroidogenesis and thyroid disrupting com-
pounds.’’ Therefore, although we have included thyroid and steroi-
dogenesis for completeness in our case study, we do not discuss
the results in any great detail.
To predict EDSP T1S outcomes from ToxCast™ and/or chemical
predictors, a Random Forest machine learning algorithm, available
in the R statistical computing environment (http://cran.
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Random Forest is an advanced predictive algorithm that combines
results from multiple classiﬁcation trees (a statistical algorithm
that selects the most predictive variables and ranges for the
outcome of interest), (Brieman, 2001). The regression mode of Ran-
dom Forest was used to directly ﬁt to the FractionPositive (see Sec-
tion 3.2 for deﬁnition) decimal values. Model ﬁtting was performed
akin to that undertaken in Rotroff et al. (2013) andmodel prediction
(cross validation) was performed similar to Thomas et al. (2012). In
the model ﬁtting approach, all the data (guideline/non-guideline in
turn) were used to both train the model (i.e., estimate regression
coefﬁcients to optimize measures of ﬁt), and obtain metrics of
the quality of the ﬁt obtained. By using the same data sets to train
the model and obtain metrics, model overﬁtting can artiﬁcially
inﬂate the prediction values. Therefore, in the model prediction
approach, a 5-fold cross-validation was carried out to reduce the
overﬁtting bias. For cross validation, 80% of the data was selected
at random to train the model, yielding a regression model for pre-
dicting EDSP outcomes from ToxCast™ predictors. The resulting
model was then tested on the 20% of the data not used in develop-
ing the model. This was done for each 20% block of data in turn, and
the entire process was repeated for each of 100 random permuta-
tions of the data set, generating a total of 500 different compari-
sons of model-based predictions to true EDSP outcomes. The
performance metrics, such as the mean squared error for the differ-
ence between model-predicted and observed values of positive
EDSP tests (i.e., FractionPositive, see deﬁnition below), were
averaged over all 100 full prediction sets to obtain the ﬁnal results.
To obtain classiﬁcation results and balanced accuracy (BA) values,
ﬁnal predicted values and the known FractionPositive values were
dichotomized. (All datasets and R software ﬁles are available in
Supplemental Material or may be obtained by contacting T. Cox
directly.)
2.2. Re-creation and evaluation of the Rotroff et al. (2013) HTS-derived
EDSP T1S endocrine prediction models
2.2.1. Data set construction
Recreating the Rotroff et al. (2013) HTS-derived EDSP T1S endo-
crine prediction models required reconstructing their datasets,
including following how dose–response data from the ToxCast™
assays were summarized and classiﬁed (e.g., as positive or negative
responses). From the results of the 18 speciﬁc ToxCast™ assays,
Rotroff et al. (2013) assessed how well counts of positive tests
could be used to classify, or ﬁt, EDSP T1S in vivo results (i.e. fraction
that were positive), compared with using count values from ran-
domly selected subsets of the 18 ToxCast™ assays. Positive hit
counts were their sole predictor, and thresholds for classifying
the number of ‘‘positive’’ hit counts (i.e., one positive E-related
assay, two positive E-related assays, etc.) were chosen to maximize
balanced accuracy. Full details of how the dose–response data
were processed were not given in the Supplementary Materials,
and despite several helpful discussions with the authors of the
HTS-derived EDSP T1S endocrine prediction models, we could not
replicate them. We therefore initially accepted the chemical-assay
binary ‘‘hit’’ values as provided, using them as inputs to data min-
ing and machine learning software available in the R statistical
computing environment.
To create our own data sets relating predictors to EDSP results,
we merged the ToxCast™ chemical-assays and EDSP result ﬁles
with a matching key (CAS registration number and Class). Compar-
ing the resulting dataset against the supporting information/data
provided in Rotroff et al. (2013) revealed one additional chemical,
benomyl, as a candidate for inclusion in the guideline A set; i.e.,
benomyl appeared in both the original ToxCast™ and EDSP data
ﬁles for A-related endpoints, and was not ﬁltered out via any ofthe exclusion criteria stated in Rotroff et al. (2013). Our analysis
therefore began with the same data used by Rotroff et al. (2013)
as far as possible, with the exception of this additional chemical.
Table 1 shows an example of the resulting data for the ﬁrst 3
variables for guideline-E combinations. Note: results for all chem-
ical-class combinations, including hit indicators, for both guideline
and non-guideline EDSP cases are provided in the Supplementary
Files.
Although the preceding data preparation steps closely followed
Rotroff et al. (2013)’s general approach, the following differences
are reﬂected in predictors (CountTC and FractionTC) and predicted
variables (FractionPositive) for guideline and non-guideline studies
in our study: (1) we considered both FractionTC and CountTC as
predictors, allowing a Class-independent input which was consid-
ered necessary since each Class, E, A, S, and T contained different
numbers of chemical-assay pairs; (2) instead of dichotomizing
FractionPositive into positive or negative classes, we provided the
raw decimal values to the prediction algorithms. For example, if
three out of the four E-related assays were positive, the value of
0.75 was used rather than 1, which had been taken to designate
positive results in Rotroff et al. (2013); (3) we considered individ-
ual ToxCast™ assay results, as well as their collective counts. Each
result was retained; and (4) all classes were modeled simulta-
neously to enable sharing of potentially predictive information.
This also resulted in larger sample sizes. However, we performed
separate analyses for guideline and non-guideline EDSP studies,
as in Rotroff et al. (2013).
2.2.2. Evaluation of the EPA 2013 HTS-derived EDSP T1S endocrine
prediction models
The challenge was therefore to determine how well FractionPos-
itive for guideline and non-guideline studies could be predicted
from CountTC, FractionTC, and the 18 assay speciﬁc hit indicators
within each EDSP class grouping. Exploratory analysis showed that
CountTC and FractionTC are signiﬁcantly correlated with Fraction-
Positive for the EDSP assays, (both guideline and non-guideline
studies), even though most individual ToxCast™ assays are signif-
icantly correlated with non-guideline EDSP results. We applied a
Random Forest machine-learning algorithm to the guideline and
non-guideline data sets described above to classify or predict the
EDSP FractionPositive values. The results are shown in Table 2.
For model-ﬁtting, the results are comparable to those of Rotroff
et al. (2013). Table 2 includes the number wrong (#Wrong) [num-
ber of instances incorrectly classiﬁed using the ﬁtted model], bal-
anced accuracy (BA), the root mean squared error (RMSE) (which
Rotroff et al., 2013 did not report) and also the corresponding
model-prediction results based on model cross-validation (CV)
using disjoint training and test sets, as previously described, with
metrics from cross-validation (denoted by CV) averaged over 100
random CV prediction sets.
The ﬁtted results for guideline studies (Table 2; using ToxCast™
indicators to classify known EDSP results) compare favorably to
the ﬁtted results obtained by Rotroff et al. (2013) (BA = 0.94 using
Random Forest versus 0.91 obtained by Rotroff et al. for the E class,
reﬂecting one additional correct classiﬁcation by Random Forest;
identical results to Rotroff et al. for the A and T classes; and slightly
lower BA for the S class). As expected, the true prediction task, using
cross validation, is more challenging. For E and A, the BA values for
prediction (BACV) are lower than the BA values for ﬁtting (BA) by
approximately 0.09 and 0.13, respectively. (As noted by Rotroff
et al. (2013), S and T responses could not be ﬁtted very well due
to limitations with these data sets (i.e., too few assays and/or
insufﬁcient positive results). The RMSE is also much higher for pre-
dicted values as compared to the ﬁtted values. Thus, the very high
BA values (>0.9) reported by Rotroff et al. (2013) for classes E and A
are higher than the cross-validation results we derived. Consistent
Table 1
Example of initial predictor variables and dependent variable (guideline-E combinations shown).
CASRN Name Class CountTC FractionTC FractionPositive
104-40-5 4-Nonylphenol E 1 0.13 0.50
140-66-9 4-(Tert-octyl)phenol E 4 0.67 1.00
521-18-6 5a-Anderostan-17B-ol-3-one E 3 0.50 1.00
1912-24-9 Atrazine E 0 0.00 0.33
17804-35-2 Benomyl E 0 0.00 0.25
50-28-2 b-Estradiol E 4 0.67 1.00
80-05-7 Bisphenol-A E 6 0.75 0.90
2425-06-1 Captafol E 0 0.00 0.33
5598-13-0 Chlorpyrifos-methyl E 2 0.25 0.00
84-74-2 Dibutyl phthalate E 1 0.13 0.00
117-81-7 Diethylhexyl phthalate E 0 0.00 0.33
66230-04-4 Esfenvalerate E 1 0.13 0.00
60168-66-0 Fearimol E 3 0.38 1.00
13311-84-7 Flutamide E 0 0.00 0.00
446-72-0 Genistein E 4 0.67 1.00
72-43-5 Methoxychlor E 3 0.38 1.00
40487-42-1 Pendimethalin E 2 0.25 1.00
52645-53-1 Permethrin E 1 0.13 0.00
67747-09-5 Prochloraz E 1 0.13 1.00
3380-34-5 Triclosan E 0 0.00 0.00
50471-44-8 Vinclozolin E 1 0.13 0.00
Legend: CountTC is the total count (number) of the 18 ToxCast predictors that were classiﬁed by Rotroff et al. as providing a positive result, for each chemical and each EDSP
assay class. For example, 7 would be entered if 7 of the 18 ToxCast assays were deemed positive for chemical X. FractionTC is the fraction of positive ToxCast results, calculated
using only relevant (non-NA) assays in the denominator. Rotroff et al. (2013) selected subgroups of the 18 ToxCast assays as being relevant for predicting the results in each of
the 4 EDSP assay classes (estrogen, androgen, steroidogenesis and thyroid (E, A, S, T)), such as 5 speciﬁc assays for androgen, and 8 or 9 for estrogen (depending upon the
chemical). If, for example, 7 of 9 ToxCast estrogen-related relevant assays were positive for chemical X, 0.78 would be entered. FractionPositive is the fraction of all EDSP
studies classiﬁed by Rotroff et al. (2013) as showing a positive result. This fraction was calculated separately for each of the 159 chemicals and within each of the 4 classes of
EDSP assays (E, A, S, T) for which data were available. (For example, FractionPositiveG for chemical X is the proportion of E-related positive studies (the uterotrophic, ﬁsh short-
term reproduction assay, ER binding, pubertal female, etc.) divided by the total number of all guideline-E studies in the data set, and FractionPositiveNG for chemical X is the
proportion of E-related positive studies (the uterotrophic, ﬁsh short-term reproduction assay, ER binding, pubertal female, etc.) divided by the total number of all non-
guideline-E studies in the data set.) Hit indicators were the 18 variables indicating the binary result for each chemical-assay combination. A ‘‘1’’ indicated a positive result, ‘‘0’’
a negative result, and ‘‘1’’ indicated cases where a result was not relevant (NA in the original ﬁles).
Table 2
Fitting and prediction results for guideline and non-guideline studies using the 18 Selected ToxCast™ assays from the EPA 2013 HTS-derived EDSP T1S endocrine prediction
models publication.
Class Count Model-ﬁtting results based on original Rotroff data Model-prediction results based on model cross-validation
# Wrong BA RMSE # Wrong CV BACV RMSECV
Guideline studies
E 21 1 0.9444 0.2092 2.98 0.8493 0.3431
A 14 1 0.9167 0.2159 2.72 0.7883 0.3352
S 17 6 0.5000 0.3902 6 0.500 0.4215
T 8 4 0.5000 0.5001 6.16 0.230 0.5717
Non-guideline studies
E 143 12 0.7209 0.2584 16.05 0.6442 0.2946
A 59 19 0.5000 0.3931 21.38 0.4926 0.4149
S 55 25 0.5000 0.4157 25.33 0.4959 0.4301
T 47 16 0.5000 0.3853 16.38 0.4954 0.4046
Legend: Class = type of assay; Count = number of instances; # Wrong = number of instances incorrectly classiﬁed using the ﬁtted model; BA = balanced accuracy metric for the
ﬁtted model; RMSE – root mean squared error between the actual FractionPositive and the model ﬁt; # WrongCV = number of instances incorrectly classiﬁed by cross-
validation prediction; BACV = balanced accuracy from cross-validation prediction; RMSECV = RMSE from cross-validation prediction. For BA and BACV, the closer a value is to
unity, the greater the model accuracy. For RMSE and RMSECV, the smaller the value, the better predictive performance of the model.
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bias in Rotroff et al.’s reported classiﬁcation performance (BA) esti-
mates compared to the results obtained using disjoint training and
test results (BACV estimates). This outcome is a likely consequence
of over-ﬁtting (arising from the use of the same data to train and
then test classiﬁcation of known EDSP results using ToxCast™
results). Notwithstanding this ﬁnding, even when cross-validation
is used, the resulting BA scores (i.e., BACV in Table 2) of 0.85 for
Class E and 0.79 for Class A are signiﬁcantly better than random
and also well above the 0.55 level mentioned for most endpoints
by Thomas et al. (2012). Thus, the major ﬁnding in the EPA 2013
HTS-derived EDSP T1S endocrine prediction model publication –
that class A and E results for guideline studies can be predicted
with substantially better than random accuracy using the 18selected ToxCast™ assays results – is supported by this cross-val-
idation analysis. Overall, the BA scores for cross validation are
lower than for ﬁtting: 0.85 compared 0.94 for class E, and 0.79
compared to 0.92 for class A. For steroidogenesis (S) and thyroid
(T), cross validation BA values were <0.5, indicating poor predictiv-
ity of the ToxCast™ assays, consistent with the ﬁndings of Rotroff
et al. (2013).
For the much larger set of non-guideline studies (Table 2), the
performance of the automatically ﬁtted Random Forest model for
class E is similar to that of Rotroff et al.’s hand-tuned model (BA
of 0.72 versus 0.74), while for class A, the BA is worse (0.50 versus
0.65). Prediction has lower BA than ﬁtting for Class E, but is almost
the same for other classes, and RMSE is only slightly lower for
ﬁtting than for prediction. Again, consistent with EPA 2013
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line studies, BA values indicated poor predictivity for steroidogen-
esis and thyroid. Compared to guideline studies, non-guideline
studies can vary greatly in data quality and study reliability, and
criteria for determining positive and negative responses are not
standardized, so the results may be, in large part, a reﬂection of
these features. Publication bias may also be an important factor
to consider; positive studies are more likely to be published, which
could skew the available data sets. A focus on quality and reliabil-
ity of the input data is warranted when constructing datasets for
use in building prediction models.2.3. Evaluation of prediction modeling using the full ToxCast assay
dataset
We also conducted an evaluation of howwell the EDSP Tier 1 out-
comes for E, A and T endpoints could be automatically predicted from
the full set of ToxCast™ assays, rather than only from the subset of 18
endocrine-related ToxCast™ assays in Table 1. Here the concentra-
tion–response data for the ToxCast™ chemicals were merged with
the Supplemental File 3 data of Rotroff et al. (2013), using CASRN as
the common key. The concentration–response data were contained
within the following ﬁles, downloaded from the ToxCast web site
(http://epa.gov/ncct/toxcast/data.html): (1) ACEA_PrimaryData_Tox
Cast-PhaseI_320Chemicals_03Feb2010.txt; (2) Attagene_PrimaryDat
a_ToxCast-PhaseI_320Chemicals-plus-controls_29Jan2010.txt; (3)
Bioseek_PrimaryData_ToxCast-PhaseI_320Chemicals_03Feb2010.txt;
(4) Cellumen_PrimaryData_ToxCast-PhaseI_320Chemicals-plus-co
ntrols_03Feb2010.txt; (5) CellzDirect_PrimaryData_ToxCast-PhaseI
_320Chemicals_29Jan2010.txt; (6) Gentronix_PrimaryData_Tox-
Cast-PhaseI_320Chemicals_14Dec2009.txt; and (7) NCGC_Primary
Data_ToxCast-PhaseI_320Chemicals_03Feb2010.txt.
For each matching chemical and each available ToxCast assay, a
binary ‘‘hit’’ indicator (0 = no, 1 = yes) of positive activity, was
independently generated. Brieﬂy the procedure was to use the
drm() (dose–response model) function of the DRC function library
in the R programming environment (http://cran.r-project.org/web/
packages/drc/) to approximate the raw concentration–response
data for each chemical and ToxCast™ assay by a continuous curve.
The resulting curves were passed to the noEffect() function of the
same library to dichotomize them. The noEffect() function performs
a signiﬁcance test comparing the given dose–response curve to a
simple linear regression with zero slope. If the function returned
a p value less than .05, a ‘‘hit’’ was recorded. To make predictions
with the full set of ToxCast™ assay data, these binary assay indica-
tors were used instead of CountTC, and FractionTC.
The main results of applying the Random Forest algorithm to
the full set of HTS (ToxCast™ assay) indicators are presented in
Table 3. Signiﬁcant improvements in ﬁt are noted, with BA scores
of 1 for classes of guideline-E and -A studies (Table 3), compared
to 0.94 and 0.92 (Table 2) achieved using 18 endocrine assays for
prediction model development. Signiﬁcant improvements in BA
for classes S and T were achieved as well. Thus, looking at BA, fully
automated methods gave signiﬁcantly better BA results than man-
ual selection for both guideline and non-guideline studies, and for
all classes. Theoretically, since the E and A responses in the utero-
trophic and Hershberger assays are receptor mediated, one might
have expected the opposite results. That is, by including all
ToxCast™ assay results, the balanced accuracy for ﬁtting would
decrease, compared to models developed only with E- and
A-speciﬁc ToxCast™ assays. However, since this is a classiﬁcation
model and ToxCast™ assays are being evaluated against known
outcomes, there are likely elements within the features of the full
suite of ToxCast™ assays that provide auxiliary value which
enables improved classiﬁcation.Along such lines, it is critically important to note that despite
their excellent performance, as measured by BA, in classifying
known EDSP outcomes based on known ToxCast™ results, the fully
automated methods do not achieve comparably high genuine pre-
dictive power, as indicated by their much lower BACV scores
(Table 3). Thus, it is apparent that (1) state-of-the-art machine
learning methods exhibit excellent ability to generate classiﬁcation
rules (ﬁtting) that describe known data points (BA > 0.9 in Table 3,
similar to Rotroff et al.’s ﬁndings), but only limited ability to
predict the outcomes of EDSP assays which have not yet been per-
formed (and/or which have not been included in the ﬁtting exer-
cise) (BACV < 0.6 for guideline studies and <0.7 for non-guideline
studies); and (2) the BA scores for EPA 2013 HTS-derived EDSP
T1S endocrine prediction models, while reﬂecting good ﬁts to
known data points, should likewise not be interpreted as necessar-
ily indicating comparably high ability to actually predict EDSP
results for tests which have not yet been performed.
2.4. Evaluation of prediction modeling using chemical property
information
For completeness, an evaluation of how well EDSP outcomes
could be predicted from chemical information alone was also
undertaken. Chemical structure data available for the 159
ToxCast™ chemicals was extracted from the ToxCast™ website
(http://epa.gov/ncct/toxcast/data.html). The ﬁle, ToxCast_Phase_1_
StructureClassiﬁers_20110110.txt, contains binary structure indi-
cators for 241 ToxCast™ chemical attributes. The structure data
set was merged with the data ﬁles described above. To make pre-
dictions with structure data, these 241 binary structure indicators
were used instead of CountTC, and FractionTC in Table 2. The
Random Forest algorithm was applied to the chemical structure
data as predictors. Table 4 shows the summary results.
The Random Forest algorithm provided an excellent ﬁt using
chemical structure data only (BA ranged from 0.70 to 1.0), espe-
cially for guideline studies. However, comparing Tables 3 and 4,
the predictions based on chemical structures are essentially the
same in quality as those based on using all ToxCast™ assay results
(BACV ranged in Table 3 from 0.32 to 0.67 and in Table 4 from 0.31
to 0.67). Using the combination of all ToxCast™ predictors and all
chemical structure predictors did not signiﬁcantly improve the
results over using either one alone (results not shown). These ﬁnd-
ings conﬁrm the ﬁnding of Thomas et al. (2012) that use of HTS
data does not greatly improve upon what can already be predicted
from chemical property data alone.
3. Conclusions regarding the EPA 2013 ToxCast HTS-derived
EDSP T1S endocrine prediction models
Our work to independently replicate and verify previously
reported results (Rotroff et al. (2013)) that showed high balanced
accuracy (BA > 0.90) values for model ﬁtting to predict E and A
results from selected ToxCast™ assay results has led to the follow-
ing major conclusions:
(1) Although it was not possible to exactly replicate the model
results of Rotroff et al. (2013) based on the documentation
and data ﬁles provided, using the same 18 selected
ToxCast™ assays as classiﬁers, BA values in excess of 90%
for E and A could be achieved by model ﬁtting of known
EDSP results for 35 guideline studies (21 in Class E and 14
in Class A).
(2) Using fully automated machine-learning techniques that are
publically available in the R statistical computing environ-
ment allows these model ﬁtting BA scores to be improved
to 100% for E and A for these same 35 chemicals.
Table 3
Fitting and prediction results for guideline and non-guideline studies using all ToxCast™ assays.
Class Count Model-ﬁtting results based on original Rotroff data Model-prediction results based on model cross-validation
# Wrong BA RMSE # Wrong CV BACV RMSECV
Guideline studies
E 15 0 1.0000 0.2651 6.18 0.5695 0.4607
A 14 0 1.0000 0.2551 5.72 0.5873 0.4765
S 17 2 0.8333 0.2303 6.9 0.5830 0.4740
T 8 1 0.8750 0.3828 5.45 0.3188 0.6366
Non-guideline studies
E 135 3 0.9063 0.1265 16.08 0.5216 0.3007
A 59 2 0.9474 0.2343 16.31 0.6744 0.4253
S 55 7 0.2291 0.2291 19.39 0.6348 0.4216
T 47 8 0.2217 0.2217 17.91 0.5561 0.4154
Legend: Class = type of assay; Count = number of instances; # Wrong = number of instances incorrectly classiﬁed using the ﬁtted model; BA – Balanced accuracy metric for the
ﬁtted model; RMSE – root mean squared error between the actual FractionPositive and the model ﬁt; # WrongCV = number of instances incorrectly classiﬁed by cross-
validation prediction; BACV = Balanced accuracy from cross-validation prediction; RMSECV = RMSE from cross-validation prediction. For BA and BACV, the closer a value is to
unity, the greater the accuracy. For RMSE and RMSECV, the smaller the value, the better prediictive performance of the model.
Table 4
Fitting and prediction results for guideline and non-guideline studies using chemical structure data.
Class Count Model-ﬁtting results based on original Rotroff data Model-prediction results based on model cross-validation
# Wrong BA RMSE # Wrong CV BACV RMSECV
Guideline studies
E 15 0 1.0000 0.2377 4.89 0.5960 0.4400
A 14 0 1.0000 0.2318 4.24 0.6708 0.4577
S 17 3 0.7500 0.2222 6.58 0.5058 0.4671
T 8 0 1.0000 0.3772 5.53 0.3088 0.6000
Non-guideline studies
E 135 6 0.8395 0.1674 16.78 0.6144 0.2961
A 59 4 0.8947 0.2579 16.85 0.6012 0.4488
S 55 11 0.7867 0.2773 26.26 0.5048 0.4616
T 47 10 0.7026 0.2392 19.15 0.4716 0.4182
Legend: Class = type of assay; Count = number of instances; # Wrong = number of instances incorrectly classiﬁed using the ﬁtted model; BA – Balanced accuracy metric for the
ﬁtted model; RMSE – root mean squared error between the actual FractionPositive and the model ﬁt; # WrongCV = number of instances incorrectly classiﬁed by cross-
validation prediction; BACV = Balanced accuracy from cross-validation prediction; RMSECV = RMSE from cross-validation prediction. For BA and BACV, the closer a value is to
unity, the greater the accuracy. For RMSE and RMSECV, the smaller the value, the better predictive performance of the model.
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forecast from ToxCast™ data with BA > 0.9 should be under-
stood to mean that these outcomes can be ﬁtted or classiﬁed
with BA > 0.9, once they are known. However, the important
practical challenge of true prediction of as-yet unknown
EDSP outcomes from ToxCast™ data appears to be much
more difﬁcult.
(4) Using cross validation methods, the E and A prediction mod-
els developed using guideline studies yielded BACV results
of 0.85 (E) and 0.79 (A), which are signiﬁcantly better than
random.
(5) There is a caveat: the activities evaluated for E and A are
based on estrogen receptor and androgen receptor interac-
tions; other modes-of-action that affect E and A signaling
(e.g., hypothalamic–pituitary–gonadal axis effects) were
not evaluated as part of this analysis or that of Rotroff
et al. (2013).
(6) Overall, most likely due to limitations in the available assays
and data sets, for S and T, using the 18 ToxCast™ assays,
both classiﬁcation and prediction were no better than
random. Similar conclusions were reached by Rotroff et al.
(2013).
(7) Somewhat surprisingly, for both guideline and non-
guideline studies, using all of the ToxCast™ assays improved
classiﬁcation (BAs ranging from 0.77 to 1.0). However, this
was not the case for predictivity using cross validation,
where BA values hovered around random chance (BACVsranged from 0.32 to 0.67). Substantially similar results were
obtained when the Random Forest algorithm was applied to
chemical structure data. These ﬁndings highlight the
importance of understanding model development based on
classiﬁcation or ﬁtting, versus model development using
cross validation.
4. Discussion: developing scientiﬁc conﬁdence in HTS/HCS
assays and prediction models based on such assays
Signiﬁcant research and development activities have focused on
generating data from Tox21 methods and, to a lesser extent,
prediction models derived from these assays. Yet, only limited
attention has been paid to systematic approaches for developing
and documenting scientiﬁc conﬁdence in these assays and
prediction models. Whether for priority setting, integrated testing
strategies, product stewardship, or regulatory decision making,
practical application of HTS/HCS assays and derived prediction
models requires development of scientiﬁc conﬁdence in the assays
and the use of assay results. This is essential so that regulatory
agencies, the regulated community, and the public can be assured
that the use of this new kind of knowledge is both scientiﬁcally
credible and relevant for decision making. The level of scientiﬁc
conﬁdence necessary for HTS assays and HTS-derived prediction
models will certainly vary by use, such that, for example, a higher
level of conﬁdence would be required for a regulatory hazard
Table 5
Major components of a scientiﬁc conﬁdence framework for prediction models derived from HTS assays.
Analytical
validation
Assessment of the biological basis and analytical performance of assays. Each HTS/HCS assay should map to a deﬁned mechanistic endpoint (e.g.,
the intermediate or key event in the mode of action or AOP). A deﬁned chemical domain of applicability, and documentation of assay performance
characteristics (reliability, sensitivity, and speciﬁcity) and transparent data sets (to enable independent veriﬁcation) should be readily available.
Qualiﬁcation Assessment of the prediction model derived from the HTS/HCS screening assays. A deﬁned algorithm for each prediction model is needed to ensure
transparency. Appropriate measures of goodness-of-ﬁt, robustness and predictivity of the prediction model need to be presented. Some prediction
models may be quantitative, others may be qualitative. Known limitations of each prediction model should also be summarized. Prediction models
should be characterized in sufﬁcient detail to facilitate review, reconstruction and independent veriﬁcation of results.
Utilization Contextual and weight-of-evidence analysis of the use (qualitative or quantitative) of the prediction model for a speciﬁc purpose. This includes
summarizing results of Analytical Validation and Qualiﬁcation steps, deﬁning the intended purpose of the prediction model and documenting/
justifying applications, based on weight of evidence, where there is sufﬁcient scientiﬁc conﬁdence to support the use of the prediction model. The
types of uses to which the prediction models could be applied include, but are not limited to: (1) priority setting, where the model is used to
identify priority substances that will go on to more detailed evaluation; (2) screening level assessment of a biomarker, where the model is used as a
surrogate data point for a biochemical endpoint or a biomarker; (3) integrated testing strategy, where the model is used to describe/predict a
hazard property in lieu of conducting a traditional animal toxicity study or (4) to predict an adverse outcome.
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select substances for more in-depth toxicity testing.
Previously, in Patlewicz et al. (2013), we discussed scientiﬁc
conﬁdence in the context of two validation frameworks, the IOM
Framework (IOM, 2010) and the OECD Validation principles
(2004), and adapted these for consideration in HTS/HCS assays.
Similarly, Hartung et al. (2013) stated that ‘‘validating the mecha-
nism of a (group of) toxicant(s) is the basis for mechanistic valida-
tion of tests that identify those toxicants,’’ and proposed that the
performance of Tox21 test methods could be addressed through
‘‘mechanistic validation’’ which focuses on biological pathways
and is carried out in six steps: (1) articulation of the pathway
(‘‘the biological/mechanistic circuitry (‘‘in the absence of xenobi-
otic challenge’’) leading to the hazard; (2) documenting the evi-
dence, based on results in validated models, that reference
chemicals that cause the hazard ‘‘perturb the biology in question;’’
(3) development of test(s) that reﬂect this biology; (4) veriﬁcation
that toxicants acting by this mechanism also do so in the test(s);
(5) veriﬁcation that antagonism or interference of the mechanism
blocks or hinders positive test results. Although not a one-to-one
match, this approach is, in essence, very similar to a well-informed
adverse outcome pathway (AOP) that includes support for a causal
link between the key event and adverse outcome (Ankley et al.,
2010). While Judson et al. (2013) agree that increasing the use of
well characterized reference compounds is important; they de-
emphasize the need for cross-laboratory testing, stressing instead
the importance of data availability to enable a ‘‘web-based, trans-
parent, and expedited peer review process.’’
Based on Patlewicz et al. (2013), the analysis reported here and
our recent efforts in developing AOPs, we propose a Scientiﬁc Con-
ﬁdence Framework for prediction models derived from HTS assays
(Table 5). This proposed framework contains three inter-related
elements: Analytical Validation, Qualiﬁcation and Utilization.
Together, these three elements should facilitate systematic,
transparent, and objective evaluation and documentation of the
scientiﬁc conﬁdence of HTS/HCS assays and their prediction mod-
els. Addressing these elements may be challenging, although it is
envisioned that the manner and extent to which these need to be
addressed will be context dependent.
To illustrate application of the proposed Scientiﬁc Conﬁdence
Framework, we considered the Rotroff et al. (2013) report and
the case study presented above. With respect to the ﬁrst
framework element, Analytical Validation, each of the 18 endo-
crine ToxCast™ assays has a deﬁned mechanistic endpoint. In
terms of accessibility to ToxCast™ data to enable independent
veriﬁcation, or reﬁnement of existing prediction models or
development of new models, EPA’s ToxCast™ program is to be
commended. All of the data were accessible from the ToxCast™
web site or from the Supplemental Materials in the Rotroff et al.
(2013) publication. However, we did not review or analyze thechemical domains of applicability or documentation of assay per-
formance characteristics (reliability, sensitivity, and speciﬁcity).
Such a review is important, and requires a detailed and separate
analysis outside the scope of this manuscript.
In terms of the second framework element, Qualiﬁcation
(assessment of the prediction model derived from the HTS/HCS
screening assays), the Rotroff et al. (2013) HTS-derived EDSP T1S
endocrine prediction models fell well short. None of the published
prediction model algorithms were transparent, nor were the algo-
rithms clearly deﬁned and documented. Input from the ﬁrst author
was helpful, but signiﬁcant efforts were still needed to reverse
engineer the prediction models. For the most part, the underlying
data sets were available to support this reverse engineering activ-
ity, however, the precise details of how dose–response data were
re-coded as binary and response indicators (using an unspeciﬁed
Hill function with somemanual adjustment) were not documented
or readily available in the Supplementary Materials. Thus,
considerable unnecessary effort was required to enable indepen-
dent veriﬁcation. In terms of documentation of measures of good-
ness-of-ﬁt, robustness and predictivity of the prediction models,
Rotroff et al. (2013), provided estimates for predictivity of classiﬁ-
cation (ﬁtting); but unbiased performance determinations (cross
validation) for prediction of as-yet unknown EDSP outcomes from
ToxCast™ data were not provided. Our analysis suggests that
focusing the assay set to those of known biological relevance
may increase the predictive performance (although not necessarily
the ﬁtting performance). With respect to use of datasets in model
development, the difference between results of guideline studies
vs. non-guideline studies should be noted. Based on our
experience, we would recommend that toxicity study databases
assembled for use in constructing predictive modeling should be
curated by experienced toxicologists, with a particular focus on
deﬁning study quality and data reliability using a predetermined
set of criteria that allow for identiﬁcation of positive versus nega-
tive responses based on accepted toxicological principles. How-
ever, the models still must be used with caution because the
domain of applicability – the structural space of substances used
to construct these classiﬁcation and prediction models – is cur-
rently limited to 21 chemicals for estrogen pathways and 14 for
androgen pathways. Thus, research and development needs to con-
tinue to develop data sets and prediction models, before prediction
models derived from HTS/HCS results can be used as standalone
algorithms to predict in vivo endocrine endpoints.
Regarding the third element of the framework, Utilization,
Rotroff et al. (2013) indicate the intent is to use these models to
‘‘predict components of EDSP T1S and related results.’’ First, we
agree with Rotroff et al. (2013), that current ToxCast results are
inadequate to predict S and T responses. For E and A, our analysis
shows that because these models were developed using ﬁtting,
they fall short in truly predicting EDSP Tier 1 E and A in vivo results.
450 Louis Anthony (Tony) Cox et al. / Regulatory Toxicology and Pharmacology 69 (2014) 443–450Nevertheless, the balanced accuracies of both the classiﬁcation
(ﬁtting) and cross validation models for E and A activities signal
signiﬁcant advancement in developing biologically-based HTS/
HCS-derived models for E and A endocrine activities. Yet, with
respect to regulatory use, a number of questions still must be
addressed concerning the acceptable range of predictivity
(balanced accuracy) of an E or A prediction model necessary to
use for a given purpose. How accurate must predictivity be for
prioritizing substances for E and A for proceeding into EDSP
screening? For bypassing certain E or A EDSP receptor-mediated
in vitro Tier 1 assays? For use in predicting results of the utero-
trophic and Hershberger assays, obviating the need for these to
be carried out in Tier 1 of the EDSP? Is there a set degree of scien-
tiﬁc conﬁdence in the performance of the assays and prediction
models, irrespective of the type of regulatory use, or, as we sug-
gested previously (Patlewicz et al., 2013), is it accepted that differ-
ent uses can allow different levels of uncertainty/conﬁdence, and, if
so, what are these, in quantitative scientiﬁc terms? How can inte-
gration of exposure data/estimates with such HTS activity-based
measures/predictions (Wetmore et al., 2012; Becker et al., 2014)
provide an improved context for priority setting and decision mak-
ing? While such questions cannot be readily answered today, they
warrant timely robust discussion within the regulatory science
community. Clearly, with the caveat that the results to date reﬂect
a limited number of substances, the ToxCast™-derived E and A
classiﬁcation and cross validation models may have considerable
utility to discriminate between substances that are a priority for
proceeding into EDSP Tier 1 screening and those that are not. For
use in EDSP, as well as for other potential applications, the Scien-
tiﬁc Conﬁdence Framework we have proposed, or a similar tool,
can assist in the transparent characterization and communication
of the performance of both assays and prediction models.
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